Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Vir Biotechnology, Inc.

11.70
+0.58005.22%
Post-market: 11.66-0.0400-0.34%19:33 EDT
Volume:1.97M
Turnover:22.98M
Market Cap:1.97B
PE:-6.89
High:12.00
Open:11.11
Low:10.97
Close:11.12
52wk High:12.00
52wk Low:4.82
Shares:168.65M
Float Shares:130.00M
Volume Ratio:0.68
T/O Rate:1.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6972
EPS(LYR):-3.1619
ROE:-26.08%
ROA:-14.51%
PB:2.01
PE(LYR):-3.70

Loading ...

OverviewCompanyNewsFilings

Sector Update: Healthcare

MT Newswires Live
·
7 hours ago

Top Midday Stories: Delta Shares Fall After Q3 EPS, Revenue Misses; Apple Reportedly Cuts iPhone 18 Pro Component Orders Due to Soft Demand

MT Newswires Live
·
8 hours ago

Vir Biotechnology gains FDA Fast Track for VIR-5500

TIPRANKS
·
Oct 08

Vir Biotechnology Says FDA Grants Fast Track Status to Prostate Cancer Drug VIR-5500

Reuters
·
Oct 08

Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

THOMSON REUTERS
·
Oct 08

Vir Biotechnology - Phase 3 Trials for Vir-5500 Anticipated to Begin in 2027

THOMSON REUTERS
·
Oct 08

Vir Biotechnology Price Target Raised to $22.00/Share from $20.00 by HC Wainwright & Co.

Dow Jones
·
Oct 07

Vir Biotechnology, Inc. : H.c. Wainwright Raises Target Price to $22 from $20

THOMSON REUTERS
·
Oct 07

Vir Names David Liu Chief Medical Officer Effective Oct. 12, 2026

Reuters
·
Oct 07

Vir Biotechnology Appoints David Liu as Chief Medical Officer

THOMSON REUTERS
·
Oct 07

Why Vaxcyte Chose A 1.5% Convertible

Macro World​
·
Oct 07

Vir Biotechnology EVP, CFO Aziz Sawaf Files Initial Beneficial Ownership Statement

Reuters
·
Oct 07

From Lilly Deal to Market Darling: Inside Ginkgo's 120% Monthly Run

Bellwether Stocks Movement
·
Oct 06

Vir to Present Expanded Phase 2 Solstice Data on Elebsiran-Tobevibart Combo in Hepatitis Delta at AASLD 2026

Reuters
·
Oct 06

One Molecule, Three Diseases, $1.55 Billion — Inside CSL's Bet

Bellwether Stocks Movement
·
Oct 05

Merck Doubled Off Its Lows — And Analysts Still See More Room

Bellwether Stocks Movement
·
Oct 05

CSL Bets $1.6 Billion on a Drug That Hasn't Finished Phase 2

Bellwether Stocks Movement
·
Oct 05

Bayer Bets $2.2 Billion That America Is Still The Best Place To Make Drugs

Macro World​
·
Oct 03

23.3% Vs 14.8%: Lilly's New Data Just Changed The Obesity Drug Playbook

Bellwether Stocks Movement
·
Oct 03

Novartis Bets $7.8 Billion On MRNA Beyond Vaccines

Options & Short Sell
·
Oct 02
More